PMV Pharma, located in Cranbury (NJ) was built on over three decades of research into p53 biology and has gained unique insights into the discovery of selective modulators of p53 and its pathways. p53, also called “guardian of the genome”, is one of the most commonly mutated proteins in human cancers and enables cancer cells to escape death. The company’s pathway modulators are small molecule drugs with a unique mechanism of action, which promises to restore p53 to its normal function, eliminating the escape route and selectively killing mutant cancer cells without affecting normal tissues.